• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Valens Announces Mailing And Filing Of Circular For Special Meeting Of Shareholders To Approve Arrangement With SNDL

    10/28/22 11:28:18 AM ET
    $SNDL
    $VLNS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    The Valens Company Inc. (NASDAQ:VLNS) (TSX:VLNS) announced the mailing of its management information circular and related documents for the special meeting of valens shareholders in connection with the previously announced plan of arrangement under section 192 of the Canada Business Corporations Act whereby SNDL Inc. (NASDAQ:SNDL) will acquire all of the issued and outstanding common shares of the company, and in return Valens shareholders will receive, for each Valens share held, 0.3334 common shares of SNDL.

    The SNDL shares to be issued to Valens shareholders represents an implied value of $1.26 per Valens share, based on the August 19, 2022 close of the SNDL shares on the Nasdaq Capital Market exchange, representing a premium of 21%, based on the 60-day volume-weighted average price of the Valens shares on the Toronto Stock Exchange for the period ending August 19, 2022, being the last trading day prior to the announcement of the arrangement, or a 48% premium based on the 10-day VWAP of the Valens shares on the TSX for the period ending June 27, 2022, being the last trading day prior to entering into a non-binding expression of interest for the arrangement. On completion of the arrangement, former Valens shareholders are expected to hold approximately 9.5% of the outstanding SNDL shares.

    The Valens board of directors, after consultation with its financial and legal advisors, and after careful consideration of, among other factors, the unanimous recommendation of the Valens special committee and the receipt of the fairness opinion of Cormark Securities, has unanimously determined that the arrangement is in the best interests of Valens, and that the consideration being offered to shareholders is fair, from a financial point of view, has unanimously approved the arrangement and recommends that the shareholders vote for the arrangement.

    The special meeting of Valens shareholders will be held on November 29, 2022, at 10:00 a.m. (Toronto time), at offices of Stikeman Elliott LLP 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1B9.

    The close of business on October 19, 2022 is the record date for the determination of Valens shareholders who will be entitled to receive notice of and vote at the meeting and at any adjournment or postponement of the meeting.

    Receipt of Interim Court Order

    On October 20, 2022, the company was granted an interim order by the Ontario Superior Court of Justice regarding the arrangement. The interim order authorizes Valens to proceed with various matters, including the holding of the meeting to consider and vote on the proposed arrangement.

    Photo: Benzinga; Sources: courtesy of jarmoluk and lindsayfox via Pixabay

    Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

    Related News

    Valens Shares Slightly Up On Declining Quarterly Revenue

    SNDL To Buy Valens For $105M In Stock Creating Cannabis Behemoth

    The Valens Company Nominates Independent Director To Board Of Directors

    Get the next $SNDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL
    $VLNS

    CompanyDatePrice TargetRatingAnalyst
    SNDL Inc.
    $SNDL
    9/3/2025$5.00Buy
    Alliance Global Partners
    SNDL Inc.
    $SNDL
    7/17/2024Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    The Valens Company Inc.
    $VLNS
    3/3/2022Market Perform → Underperform
    Raymond James
    More analyst ratings

    $SNDL
    $VLNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL to Report First Quarter 2026 Financial Results on April 29, 2026

    EDMONTON, Alberta, April 15, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2026 financial results for the period ended March 31, 2026, before markets open on Wednesday, April 29, 2026. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on April 29, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/9eyekwcv  ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis com

    4/15/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces Leadership Transition for Cannabis Segment

    EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") announced today that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL's current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours. ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquo

    3/30/26 5:00:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    4/15/26 4:35:07 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    3/30/26 5:35:45 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    3/12/26 6:55:05 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Financials

    Live finance-specific insights

    View All

    SNDL to Report First Quarter 2026 Financial Results on April 29, 2026

    EDMONTON, Alberta, April 15, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2026 financial results for the period ended March 31, 2026, before markets open on Wednesday, April 29, 2026. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on April 29, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/9eyekwcv  ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis com

    4/15/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces Leadership Transition for Cannabis Segment

    EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") announced today that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL's current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours. ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquo

    3/30/26 5:00:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care